Screener / SEC EDGAR /CIK 0001773751 /10-K filed Feb 23, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Offices & Clinics of Doctors of Medicine

Hims & Hers Health, Inc. HIMS

Compare with peers Embed
Earnings releases

Latest results release: Nov 9, 2026

8-K item 2.02, exhibit 99

What HIMS's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 9, 2026 · EX-99.1

Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results

Open on SEC

Tightens full year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion and reduces Adjusted EBITDA guidance to a range of $257 million to $277 million SAN FRANCISCO, November 9, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026.

“In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them,” said Andrew Dudum, co-founder and CEO. “Everything we’re doing, from expanding the treatments and specialties we make available, to rolling out an AI-native experience to support every customer’s care, informed by leading minds in health and science, is designed to meet that higher bar. The platform people can rely on for their health every day, in every category, and every market, is the platform that will transform the industry. We believe we are building that platform.”

“In the third quarter, we continued to apply what we’ve learned to make deliberate strategic decisions to position Hims & Hers for durable, multi-year growth,” said Yemi Okupe, Chief Financial Officer. “Revenue grew 49% year-over- year, our second consecutive quarter of acceleration, with domestic revenue up 21% year-over-year and international revenue up more than 300% year-over-year. We delivered those results while intentionally pacing marketing spend ahead of several planned expansions to our platform in the fourth quarter, which we expect will set us up well heading into 2027. Our strong balance sheet and durable cash flow generation give us the flexibility to invest with conviction behind our long-term objective of becoming the first place people turn for their daily health needs, globally.”

was $890.4 million for the third quarter of 2026 compared to $599.0 million for the third quarter of 2025, an increase of 49% year-over-year.

was 57% for the third quarter of 2026 compared to 74% for the third quarter of 2025.

was $33.0 million for the third quarter of 2026 compared to net income of $15.8 million for the third quarter of 2025.

was $82.4 million for the third quarter of 2026 compared to $78.4 million for the third quarter of 2025.

was $65.4 million for the third quarter of 2026 compared to $148.7 million for the third quarter of 2025.

was $26.0 million for the third quarter of 2026 compared to $79.4 million for the third quarter of 2025.

Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net (loss) income and net cash provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States (“U.S. GAAP”), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading “Non-GAAP Financial Measures”.

• Adjusted EBITDA of $70 million to $90 million, reflecting an Adjusted EBITDA margin of 8% to 10%.

• Adjusted EBITDA of $257 million to $277 million, reflecting an Adjusted EBITDA margin of 8% to 9%.

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward- Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward- looking statements.

We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Hims & Hers will host a conference call to review the third quarter 2026 results on November 9, 2026, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (833) 461-5787 for U.S. participants and +1 (585) 542-9983 for international participants, and referencing conference ID #461 746 058. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit our corporate website, himsandhershealth.com, and our investor relations website, investors.hims.com.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assumes,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2026 and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, the markets accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; potential strategic investments, partnerships, or collaborations, and the expected timing or outcome of any such investments, partnerships, or collaborations; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions; changes in our product or offering mix, and the timing and market acceptance of any new products or offerings; the timing and anticipated effect of any pending or recently completed acquisitions; the success and utility of our business model; our market opportunity; our ability to scale our business and expand internationally; the growth of certain of our specialties; our ability to innovate on and expand the scope of our offerings and experiences, including through the use of diagnostics, data analytics and artificial intelligence; our ability to reinvest into the customer experience; and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions or statements in relation to any such legal and regulatory requirements. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of November 9, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the

forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Our consolidated revenue primarily comprises online sales of health and wellness products through our websites and mobile applications, including prescription and non-prescription products, as well as services, primarily consisting of medical consultation services, membership-based access, post-consultation service support, and delivery of laboratory testing results, as applicable. Our online sales are net of refunds, credits, and chargebacks, and include revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. A substantial majority of our online sales are subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. This revenue also includes sales from customers who have made one-time purchases.

represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States.

represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States.

are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers.

is defined as total revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period.

are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 605,604 $ 228,616 Short-term available-for-sale 106,617 348,876 investments Receivables, net 427,847 32,149 Inventory 107,848 80,128 Prepaid expenses and other current 73,186 77,869 assets Total current assets 1,321,102 767,638 Long-term available-for-sale — 351,263 investments Goodwill 1,110,684 278,325 Property, equipment, and 391,079 311,930 software, net Intangible assets, net 397,261 196,116 Operating lease 176,861 137,046 right-of-use assets Deferred tax assets, net 121,118 82,707 Other long-term assets 28,757 29,680 Total assets $ 3,546,862 $ 2,154,705 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 515,690 $ 143,278 Accrued liabilities 200,100 77,039 Deferred revenue 144,074 127,160 Deferred acquisition 478,595 1,479 payable Earn-out consideration 86,638 50,632 Operating lease liabilities 10,850 4,843 Total current liabilities 1,435,947 404,431 Convertible senior notes, 1,367,393 972,580 net Operating lease liabilities 182,513 143,167 Deferred acquisition 84,503 5,484 payable Earn-out consideration 84,128 53,009 Deferred tax liabilities, 27,961 28,856 net Other long-term liabilities 9,120 6,250 Total liabilities 3,191,565 1,613,777 Commitments and contingencies Stockholders' equity: Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 226,020,475 and 218,867,898 shares issued and outstanding as of September 30, 2026 and December 31, 2025, 23 23 respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of September 30, 2026 and December 31, 2025 Additional paid-in capital 711,250 652,383 Accumulated other comprehensive (loss) -30,759 2,294 income Accumulated deficit -325,217 -113,772 Total stockholders' equity 355,297 540,928 Total liabilities and stockholders' $ 3,546,862 $ 2,154,705 equity

______________ (1) Includes stock-based compensation expense as follows (in thousands):

Nine Months Ended September 30, Operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net (loss) income $ -211,445 $ 107,764 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and 89,640 36,410 amortization Stock-based 143,455 100,756 compensation Change in fair value of equity -16,167 — securities Change in fair value 18,048 7,626 of liabilities Net accretion on -190 -1,313 securities Benefit from deferred -36,124 -9,484 taxes Impairment of 1,148 531 long-lived assets Amortization of debt discount and 5,989 2,790 issuance costs Non-cash operating 15,857 7,905 lease cost Non-cash acquisition-related 38,345 4,961 costs Non-cash restructuring and other related 28,462 — charges included within cost of revenue Non-cash other 10,106 -2,129 Changes in operating assets and liabilities: Receivables, net -323,919 -16,119 Inventory -35,218 -40,103 Prepaid expenses and other current 12,040 -38,263 assets Other long-term assets -25,305 -5 Accounts payable 351,189 76,098 Accrued liabilities 76,737 -41,146 Deferred revenue 5,195 43,079 Earn-out consideration -12,058 — Deferred acquisition -9,089 — payable Operating lease -9,405 -664 liabilities Other long-term 1,519 — liabilities Net cash provided by operating 118,810 238,694 activities Investing activities Purchases of available-for-sale — -713,556 investments Maturities of available-for-sale 142,522 72,757 investments Proceeds from sales of available-for-sale 448,814 — investments Purchases of property, equipment, and -89,050 -166,657 intangible assets Investment in website development and -18,947 -12,053 internal-use software Deferred consideration paid for -130,346 — acquisition Acquisition of businesses, net of -318,108 -121,773 cash acquired Purchases of equity -11,217 — securities Payments for -10,000 — investment earn-outs Net cash provided by (used in) investing 13,668 -941,282 activities Financing activities Proceeds from issuance of convertible 390,425 970,000 senior notes, net of debt discount Purchases of capped calls related to -36,748 -47,800 convertible senior notes Proceeds from exercise of vested stock 13,282 9,796 options Payments for taxes related to net share -81,232 -94,955 settlement of equity awards Proceeds from employee stock purchase 3,846 2,970 plan Payments for acquisition-related -43,682 — earn-out consideration Payments for debt -939 -3,390 issuance costs Repurchases of common — -9,479 stock Net cash provided by financing 244,952 827,142 activities Foreign currency effect on cash and -442 -216 cash equivalents Increase in cash, cash equivalents, and 376,988 124,338 restricted cash Cash, cash equivalents, and restricted 228,616 221,440 cash at beginning of period Cash, cash equivalents, and $ 605,604 $ 345,778 restricted cash at end of period Supplemental disclosures of cash flow information Cash (received) paid for taxes, net of $ -2,168 $ 23,430 refunds Cash paid for interest 2,121 — Non-cash investing and financing activities Purchases of property, equipment, and intangible assets $ 11,718 $ 36,841 included in accounts payable and accrued liabilities Right-of-use asset obtained in exchange 40,166 132,837 for lease liability Common stock issued, contingent and deferred consideration, additional 886,287 193,890 consideration payable, and liabilities assumed in connection with acquisition of businesses Proceeds from sales of equity securities 33,583 — included in receivables, net Issuance of common stock in connection — 12,760 with asset acquisition Common stock to be issued for asset acquisition — 6,380 indemnification holdback

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure), each as defined below. We also present Adjusted Gross Profit, Adjusted Marketing, Adjusted Operations and support, Adjusted Technology and development, Adjusted General and administrative (collectively, Adjusted Operating Expenses), and Adjusted Net Income (Loss) (each of which are non-GAAP financial measures). We use Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss), when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net (loss) income before stock-based compensation; depreciation and amortization; acquisition, transaction, and investment earn-out costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, (ii) transaction professional services, and (iii) earn-outs payable under non- recurring investment agreements); other non-recurring items (which includes other non-cash, non-recurring costs, such as costs incurred when exiting insignificant lines of business, or other costs which are not related to continuing business operations); foreign currency gains and losses, net; restructuring and other related charges that are considered non-recurring; payroll tax expense related to stock-based compensation; interest income and expense, net; legal contingencies; impairment of long-lived assets; change in fair value of liabilities; income taxes; and change in fair value of equity securities. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

In the third quarter of 2026, we revised our definition of Adjusted EBITDA to include foreign currency gains and losses, net as a result of our recent international expansion. Foreign currency gains and losses, net were not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation.

In the first quarter of 2026, we announced a strategic shift for our United States weight loss offering ("2026 US WL Announcement"). As a result, we evolved our United States weight loss offering to match our global approach towards providing access to branded GLP-1 medications, and offering access to compounded GLP-1 medications

through our platform on a limited scale. In connection with the strategic shift, we revised our definition of Adjusted EBITDA to include restructuring and other related charges that are considered non-recurring, as we believe these costs are distinguishable from ongoing operating costs and do not reflect current or expected performance of our ongoing operations. These costs consist of inventory write-downs, third-party costs, and non-recurring employee compensation charges, all of which were incurred directly as a result of the 2026 US WL Announcement. Additional restructuring and other related charges were incurred in the second and third quarters of 2026, and to the extent that we incur further restructuring and other related charges in connection with the 2026 US WL Announcement in future periods, these costs will be presented consistently with our current presentation. As we did not record any non-recurring restructuring and other related charges in prior years, prior period disclosures were not impacted.

In the second quarter of 2025, we revised our definition of Adjusted EBITDA to include payroll tax expense related to stock-based compensation, which comprises employer taxes incurred upon vesting of restricted stock units and upon exercise of nonqualified stock options. As a result of recent trends in our stock price, this amount was not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non- recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net (loss) income and other U.S. GAAP results.

Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. “Free Cash Flow” is defined as net cash provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.

Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non- discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash provided by operating activities and other U.S. GAAP results. Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation (In Thousands, Unaudited)

Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) are key performance measures that our management uses to assess our operating performance. Because Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes. “Adjusted Gross Profit” is defined as gross profit adjusted for restructuring and other related charges included within cost of revenue. “Adjusted gross margin” is defined as Adjusted Gross Profit divided by revenue. “Adjusted Marketing” is defined as marketing expense adjusted for stock-based compensation. “Adjusted Operations and support” is defined as operations and support expense adjusted for stock-based compensation and restructuring and other related charges included within operating expenses. “Adjusted Technology and development” is defined as technology and development expense adjusted for acquisition, transactions, and investment earn-out costs and stock-based compensation. “Adjusted General and administrative” is defined as general and administrative expense adjusted for stock-based compensation, acquisition, transaction, and investment earn-out costs, and legal contingencies. “Adjusted Net Income (Loss)” represents Net (Loss) Income adjusted for acquisition, transaction, and investment earn-out costs, restructuring and other related charges, and legal contingencies, net of related tax effects.

Some of the limitations of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) include that they omit certain costs and charges, and therefore do not reflect all expenses that impact the corresponding U.S. GAAP results. In evaluating Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss), you should be aware that in the future we may incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss). When evaluating our performance, you should consider Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) in addition to, and not as a substitute for, other financial performance measures, including our net (loss) income and other U.S. GAAP results. Gross Profit to Adjusted Gross Profit Reconciliation

Full text with the tables
     Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results      
                                                                                
    Revenue of approximately $890 million, up 49% year-over-year in Q3 2026     
                                                                                
    Subscribers grew to nearly 2.8 million, up 13% year-over-year in Q3 2026    
                                                                                
 Tightens full year 2026 revenue guidance to a range of $3.13 billion to $3.15  
billion and reduces Adjusted EBITDA guidance to a range of $257 million to $277 
                                    million                                     
SAN FRANCISCO, November 9, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the
“Company”, NYSE: HIMS), the leading global health and wellness platform, today
announced financial results for the third quarter ended September 30, 2026.

“In healthcare, whoever owns the customer relationship wins, and that’s exactly
what we’re building toward at Hims & Hers. Today, customers want real choice,
real value, and a care team that knows them,” said Andrew Dudum, co-founder and
CEO. “Everything we’re doing, from expanding the treatments and specialties we
make available, to rolling out an AI-native experience to support every
customer’s care, informed by leading minds in health and science, is designed to
meet that higher bar. The platform people can rely on for their health every
day, in every category, and every market, is the platform that will transform
the industry. We believe we are building that platform.”

“In the third quarter, we continued to apply what we’ve learned to make
deliberate strategic decisions to position Hims & Hers for durable, multi-year
growth,” said Yemi Okupe, Chief Financial Officer. “Revenue grew 49% year-over-
year, our second consecutive quarter of acceleration, with domestic revenue up
21% year-over-year and international revenue up more than 300% year-over-year.
We delivered those results while intentionally pacing marketing spend ahead of
several planned expansions to our platform in the fourth quarter, which we
expect will set us up well heading into 2027. Our strong balance sheet and
durable cash flow generation give us the flexibility to invest with conviction
behind our long-term objective of becoming the first place people turn for their
daily health needs, globally.”
                                                                                
  Key Business Metrics                                                          
                                                                                
(In Thousands, Except for Monthly Revenue per Average Subscriber, Unaudited)
                                                                                
        Th…                                   Ni…                               
        Mo…                                   Mo…                               
  S…    En…                                   En…                               
  (…    Se…                                   Se…                               
  of    30,                     %             30,                   %           
  p…    20…  2,…    20…  2,…    Ch…  13  %    20…  2…    20…  2…    Ch…  13  %  
 ────────────────────────────────────────────────────────────────────────────── 
  M…                                                                            
  R…                                                                            
  p…    $    105    $     81         30  %    $    94    $    82         15  %  
  A…                                                                            
  S…                                                                            
                                                                                
                                                                                
  Revenue                                                                       
                                                                                
(In Thousands, Unaudited)
                                                                                
             Th…                                   N…                           
             Mo…                                   M…                           
             En…                                   E…                           
             Se…                %                  S…               %           
        20…  30,    20…         Ch…           20…  3…    20…        Ch…         
 ────────────────────────────────────────────────────────────────────────────── 
  U…                                                                            
  S…    $    65…    $    54…         21  %    $    1…    $    1…          9  %  
  R…                                                                            
  R…                                                                            
  of                                                                            
  t…         23…         55…         3…  %         4…         7…         5…  %  
  W…                                                                            
  R…                                                                            
  T…    $    89…    $    59…         49  %    $    2…    $    1…         30  %  
  r…                                                                            
                                                                                
                                                                                
  Third Quarter 2026 Financial Highlights                                       
                                                                                
•
                                                                                
  Revenue                                                                       
                                                                                
was $890.4 million for the third quarter of 2026 compared to $599.0 million for
the third quarter of 2025, an increase of 49% year-over-year.

•
                                                                                
  Gross margin                                                                  
                                                                                
was 57% for the third quarter of 2026 compared to 74% for the third quarter of
2025.

•
                                                                                
  Net loss                                                                      
                                                                                
was $33.0 million for the third quarter of 2026 compared to net income of $15.8
million for the third quarter of 2025.

•
                                                                                
  Adjusted EBITDA                                                               
                                                                                
was $82.4 million for the third quarter of 2026 compared to $78.4 million for
the third quarter of 2025.

•
                                                                                
  Net cash provided by operating activities                                     
                                                                                
was $65.4 million for the third quarter of 2026 compared to $148.7 million for
the third quarter of 2025.

•
                                                                                
  Free Cash Flow                                                                
                                                                                
was $26.0 million for the third quarter of 2026 compared to $79.4 million for
the third quarter of 2025.

Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net
(loss) income and net cash provided by operating activities, respectively, their
most comparable financial measures under generally accepted accounting
principles in the United States (“U.S. GAAP”), have been provided in this press
release in the accompanying tables. Additional information about Adjusted EBITDA
and Free Cash Flow is also included below under the heading “Non-GAAP Financial
Measures”.
                                                                                
  Financial Outlook                                                             
                                                                                
Hims & Hers is providing the following guidance:

For the fourth quarter 2026, we expect:

• Revenue of $875 million to $895 million.

• Adjusted EBITDA of $70 million to $90 million, reflecting an Adjusted EBITDA
margin of 8% to 10%.

For the full year 2026, we expect:

• Revenue of $3.13 billion to $3.15 billion.

• Adjusted EBITDA of $257 million to $277 million, reflecting an Adjusted EBITDA
margin of 8% to 9%.

The guidance provided above constitutes forward-looking statements and actual
results may differ materially. Refer to the “Cautionary Note Regarding Forward-
Looking Statements” safe harbor section below for information on the factors
that could cause our actual results to differ materially from these forward-
looking statements.

We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and
have not reconciled forward-looking Adjusted EBITDA to its most directly
comparable U.S. GAAP measure, net income or loss, because we cannot predict with
reasonable certainty the ultimate outcome of certain components of such
reconciliations, including market-related assumptions that are not within our
control, or others that may arise, without unreasonable effort. For these
reasons, we are unable to assess the probable significance of the unavailable
information, which could materially impact the amount of future net income or
loss. See “Non-GAAP Financial Measures” for additional important information
regarding Adjusted EBITDA.
                                                                                
  Conference Call                                                               
                                                                                
Hims & Hers will host a conference call to review the third quarter 2026 results
on November 9, 2026, at 5:00 p.m. ET. The conference call can be accessed by
dialing +1 (833) 461-5787 for U.S. participants and +1 (585) 542-9983 for
international participants, and referencing conference ID #461 746 058. A live
audio webcast will be available online at investors.hims.com. A replay of the
call will be available via webcast for on-demand listening shortly after the
completion of the call at the same link.
                                                                                
  About Hims & Hers Health, Inc.                                                
                                                                                
Hims & Hers is the leading global health and wellness platform on a mission to
help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in
life. That’s why we’re building a future where nothing stands in the way of
harnessing this power. Hims & Hers normalizes health & wellness challenges—and
innovates on their solutions—to make feeling happy and healthy easy to achieve.
No two people are the same, so the Company provides access to personalized care
designed for results.

For more information, please visit our corporate website, himsandhershealth.com,
and our investor relations website, investors.hims.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
can be identified by the use of forward-looking terminology, including the words
“believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,”
“assumes,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,”
“continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,”
“opportunity,” “confidence,” “foundation,” “groundwork,” or “should,” or, in
each case, their negative or other variations or comparable terminology. There
can be no assurance that actual results will not materially differ from
expectations. Such statements include, but are not limited to, any statements
relating to our financial outlook and guidance, including our mission to drive
top-line revenue growth and profitability and our ability to attain our 2026 and
long-term financial and operational targets; our expected future financial and
business performance, including with respect to the Hims & Hers platform, our
marketing campaigns, investments in innovation, the solutions accessible on our
platform, the markets accessible on our platform, and our infrastructure, and
the underlying assumptions with respect to the foregoing; potential strategic
investments, partnerships, or collaborations, and the expected timing or outcome
of any such investments, partnerships, or collaborations; statements relating to
events and trends relevant to us, including with respect to our regulatory
environment, financial condition, results of operations, short- and long-term
business operations, objectives, strategy, and financial needs; expectations
regarding our mobile applications, market acceptance, user experience, customer
retention, brand development, our ability to invest and generate a return on any
such investment, customer acquisition costs, operating efficiencies and leverage
(including our fulfillment capabilities), the effect of any pricing decisions;
changes in our product or offering mix, and the timing and market acceptance of
any new products or offerings; the timing and anticipated effect of any pending
or recently completed acquisitions; the success and utility of our business
model; our market opportunity; our ability to scale our business and expand
internationally; the growth of certain of our specialties; our ability to
innovate on and expand the scope of our offerings and experiences, including
through the use of diagnostics, data analytics and artificial intelligence; our
ability to reinvest into the customer experience; and our ability to comply with
the extensive, complex and evolving legal and regulatory requirements applicable
to our business, including without limitation state and federal healthcare,
privacy and consumer protection laws and regulations, and the effect or outcome
of litigation or governmental actions or statements in relation to any such
legal and regulatory requirements. These statements are based on management’s
current expectations, but actual results may differ materially due to various
factors.

Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, the forward-looking statements contained in this press
release are based on our current expectations, assumptions, and beliefs
concerning future developments and their potential effects on us. Future
developments affecting us may not be those that we have anticipated. These
forward-looking statements involve a number of risks, uncertainties (some of
which are beyond our control) and other assumptions that may cause actual
results or performance to be materially different from those expressed or
implied by these forward-looking statements. These risks and uncertainties
include, but are not limited to, those factors described in the Risk Factors and
other sections of our most recently filed Quarterly Report on Form 10-Q, our
most recently filed Annual Report on Form 10-K, and other current and periodic
reports we file from time to time with the Securities and Exchange Commission
(the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of
our assumptions prove incorrect, actual results may vary in material respects
from those projected in these forward-looking statements. The forward-looking
statements contained in this press release are made only as of November 9, 2026.
We undertake no obligation (and expressly disclaim any obligation) to update or
revise any forward-looking statements, or to update the reasons actual results
could differ materially from those anticipated in the forward-looking
statements, whether as a result of new information, future events or otherwise,
except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties
because they relate to events and depend on circumstances that may or may not
occur in the future. We caution you that forward-looking statements are not
guarantees of future performance and that our actual results of operations,
financial condition and liquidity, and developments in the industry in which we
operate may differ materially from those made in or suggested by the

forward-looking statements contained in reports we have filed or will file with
the Commission, including our most recently filed Quarterly Report on Form 10-Q,
our most recently filed Annual Report on Form 10-K, and other current and
periodic reports we file from time to time. In addition, even if our results of
operations, financial condition and liquidity, and developments in the industry
in which we operate are consistent with the forward-looking statements contained
in such reports, those results or developments may not be indicative of results
or developments in subsequent periods.
                                                                                
  Key Business Metrics                                                          
                                                                                
Our consolidated revenue primarily comprises online sales of health and wellness
products through our websites and mobile applications, including prescription
and non-prescription products, as well as services, primarily consisting of
medical consultation services, membership-based access, post-consultation
service support, and delivery of laboratory testing results, as applicable. Our
online sales are net of refunds, credits, and chargebacks, and include revenue
recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to
deferred revenue and returns reserve. A substantial majority of our online sales
are subscription-based, where customers agree to be billed on a recurring basis
to have products and services automatically delivered to them. This revenue also
includes sales from customers who have made one-time purchases.
                                                                                
  “United States Revenue”                                                       
                                                                                
represents the sales of products and services by our consolidated legal entities
operating within jurisdictions located inside of the United States.
                                                                                
  “Rest of the World Revenue”                                                   
                                                                                
represents the sales of products and services by our consolidated legal entities
operating within jurisdictions located outside of the United States.
                                                                                
  “Subscribers”                                                                 
                                                                                
are customers who have one or more “Subscriptions” pursuant to which they have
agreed to be automatically billed on a recurring basis at a defined cadence. The
Subscription billing cadence is typically defined as a number of days (for
example, billed every 30 days or every 90 days), which are excluded from our
reporting when payment has not occurred at the contracted billing cadence.
Subscribers can cancel or snooze Subscriptions in between billing periods to
stop receiving additional products and/or services and can reactivate
Subscriptions to continue receiving additional products and/or services.
Customers who have made one-time purchases are not considered Subscribers.
                                                                                
  “Monthly Revenue per Average Subscriber”                                      
                                                                                
is defined as total revenue divided by “Average Subscribers”, which amount is
then further divided by the number of months in a period.
                                                                                
  “Average Subscribers”                                                         
                                                                                
are calculated as the sum of the Subscribers at the beginning and end of a given
period divided by 2.
                                                                                
                     CONDENSED CONSOLIDATED BALANCE SHEETS                      
                                                                                
           (In Thousands, Except Share and Per Share Data, Unaudited)           
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash equivalents      $             605,604    $            228,616  
  Short-term                                                                    
  available-for-sale                           106,617                 348,876  
  investments                                                                   
  Receivables, net                             427,847                  32,149  
  Inventory                                    107,848                  80,128  
  Prepaid expenses and other                                                    
  current                                       73,186                  77,869  
  assets                                                                        
  Total current assets                       1,321,102                 767,638  
  Long-term                                                                     
  available-for-sale                                 —                 351,263  
  investments                                                                   
  Goodwill                                   1,110,684                 278,325  
  Property, equipment, and                     391,079                 311,930  
  software, net                                                                 
  Intangible assets, net                       397,261                 196,116  
  Operating lease                              176,861                 137,046  
  right-of-use assets                                                           
  Deferred tax assets, net                     121,118                  82,707  
  Other long-term assets                        28,757                  29,680  
  Total assets                   $           3,546,862    $          2,154,705  
  Liabilities and                                                               
  stockholders' equity                                                          
  Current liabilities:                                                          
  Accounts payable               $             515,690    $            143,278  
  Accrued liabilities                          200,100                  77,039  
  Deferred revenue                             144,074                 127,160  
  Deferred acquisition                         478,595                   1,479  
  payable                                                                       
  Earn-out consideration                        86,638                  50,632  
  Operating lease liabilities                   10,850                   4,843  
  Total current liabilities                  1,435,947                 404,431  
  Convertible senior notes,                  1,367,393                 972,580  
  net                                                                           
  Operating lease liabilities                  182,513                 143,167  
  Deferred acquisition                          84,503                   5,484  
  payable                                                                       
  Earn-out consideration                        84,128                  53,009  
  Deferred tax liabilities,                     27,961                  28,856  
  net                                                                           
  Other long-term liabilities                    9,120                   6,250  
  Total liabilities                          3,191,565               1,613,777  
  Commitments and                                                               
  contingencies                                                                 
  Stockholders' equity:                                                         
  Common stock – Class A                                                        
  shares, par value                                                             
  $0.0001, 2,750,000,000                                                        
  shares authorized                                                             
  and 226,020,475 and                                                           
  218,867,898 shares                                                            
  issued and outstanding as                                                     
  of September                                                                  
  30, 2026 and December 31,                                                     
  2025,                                             23                      23  
  respectively; Class V                                                         
  shares, par value                                                             
  $0.0001, 10,000,000 shares                                                    
  authorized                                                                    
  and 8,377,623 shares issued                                                   
  and                                                                           
  outstanding as of September                                                   
  30, 2026 and                                                                  
  December 31, 2025                                                             
  Additional paid-in capital                   711,250                 652,383  
  Accumulated other                                                             
  comprehensive (loss)                         -30,759                   2,294  
  income                                                                        
  Accumulated deficit                         -325,217                -113,772  
  Total stockholders' equity                   355,297                 540,928  
  Total liabilities and                                                         
  stockholders'                  $           3,546,862    $          2,154,705  
  equity                                                                        
                                                                                
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME 
                                                                                
           (In Thousands, Except Share and Per Share Data, Unaudited)           
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Rev…    $     890,…       $     598,…       $     2,25…       $     1,72…     
  Cost                                                                          
  of            381,…             156,…             864,…             440,…     
  rev…                                                                          
  Gro…          509,…             442,…             1,38…             1,28…     
  pro…                                                                          
  Gro…                                                                          
  mar…             57  %             74  %             62  %             75  %  
  %                                                                             
  Ope…                                                                          
  exp…                                                                          
  Mar…          247,…             232,…             731,…             681,…     
  Ope…                                                                          
  and           107,…             76,8…             299,…             206,…     
  sup…                                                                          
  Tec…                                                                          
  and           69,3…             40,5…             171,…             108,…     
  dev…                                                                          
  Gen…                                                                          
  and           151,…             80,6…             426,…             196,…     
  adm…                                                                          
  Tot…                                                                          
  ope…          575,…             430,…             1,62…             1,19…     
  exp…                                                                          
  (Lo…                                                                          
  inc…          -66,…             11,8…             -241…             96,4…     
  from                                                                          
  ope…                                                                          
  Oth…                                                                          
  inc…                                                                          
  (ex…                                                                          
  Cha…                                                                          
  in                                                                            
  fair                                                                          
  val…          21,1…                 —             16,1…                 —     
  of                                                                            
  equ…                                                                          
  sec…                                                                          
  Cha…                                                                          
  in                                                                            
  fair          3,821             -7,6…             -18,…             -7,6…     
  val…                                                                          
  of                                                                            
  lia…                                                                          
  Oth…                                                                          
  (ex…          -5,0…             8,042             3,108             16,7…     
  inc…                                                                          
  net                                                                           
  Tot…                                                                          
  oth…          19,8…               416             1,227             9,144     
  inc…                                                                          
  net                                                                           
  (Lo…                                                                          
  inc…                                                                          
  bef…          -46,…             12,2…             -240…             105,…     
  inc…                                                                          
  tax…                                                                          
  Ben…                                                                          
  from          13,2…             3,551             28,9…             2,193     
  inc…                                                                          
  tax…                                                                          
  Net                                                                           
  (lo…          -33,…             15,7…             -211…             107,…     
  inc…                                                                          
  Oth…                                                                          
  com…          15,2…                99             -33,…             1,245     
  inc…                                                                          
  (lo…                                                                          
  Tot…                                                                          
  com…    $     -17,…       $     15,8…       $     -244…       $     109,…     
  (lo…                                                                          
  inc…                                                                          
  Net                                                                           
  (lo…                                                                          
  inc…                                                                          
  per                                                                           
  sha…                                                                          
  att…                                                                          
  to                                                                            
  com…                                                                          
  sto…                                                                          
  Bas…    $     -0.14       $      0.07       $     -0.91       $      0.48     
  Dil…    $     -0.14       $      0.06       $     -0.91       $      0.43     
  Wei…                                                                          
  ave…                                                                          
  sha…                                                                          
  out…                                                                          
  Bas…          233,…             226,…             231,…             224,…     
  Dil…          233,…             248,…             231,…             255,…     
                                                                                
______________
(1) Includes stock-based compensation expense as follows (in thousands):
                                                                                
                      Three                              Nine                   
                     Months                            Months                   
                      Ended                             Ended                   
                   Septemb…                          Septemb…                   
             2026       30,    2025            2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Market…    $        4,135    $      3,116    $        9,954    $       9,325  
  Operat…                                                                       
  and                10,864           5,452            23,993           13,037  
  support                                                                       
  Techno…                                                                       
  and                12,555           4,842            25,190           14,134  
  develo…                                                                       
  General                                                                       
  and                36,923          26,762            84,318           64,260  
  admini…                                                                       
  Total                                                                         
  stock-…    $       64,477    $     40,172    $      143,455    $     100,756  
  compen…                                                                       
  expense                                                                       
                                                                                
                                                                                
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS                 
                                                                                
                           (In Thousands, Unaudited)                            
                                                                                
                            Nine Months Ended                                   
                            September 30,                                       
  Operating activities      2026                                2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net (loss) income         $                       -211,445    $      107,764  
  Adjustments to                                                                
  reconcile net (loss)                                                          
  income to net cash                                                            
  provided by operating                                                         
  activities:                                                                   
  Depreciation and                                    89,640            36,410  
  amortization                                                                  
  Stock-based                                        143,455           100,756  
  compensation                                                                  
  Change in fair value                                                          
  of equity                                          -16,167                 —  
  securities                                                                    
  Change in fair value                                18,048             7,626  
  of liabilities                                                                
  Net accretion on                                      -190            -1,313  
  securities                                                                    
  Benefit from deferred                              -36,124            -9,484  
  taxes                                                                         
  Impairment of                                        1,148               531  
  long-lived assets                                                             
  Amortization of debt                                                          
  discount and                                         5,989             2,790  
  issuance costs                                                                
  Non-cash operating                                  15,857             7,905  
  lease cost                                                                    
  Non-cash                                                                      
  acquisition-related                                 38,345             4,961  
  costs                                                                         
  Non-cash restructuring                                                        
  and other related                                   28,462                 —  
  charges included                                                              
  within cost of revenue                                                        
  Non-cash other                                      10,106            -2,129  
  Changes in operating                                                          
  assets and                                                                    
  liabilities:                                                                  
  Receivables, net                                  -323,919           -16,119  
  Inventory                                          -35,218           -40,103  
  Prepaid expenses and                                                          
  other current                                       12,040           -38,263  
  assets                                                                        
  Other long-term assets                             -25,305                -5  
  Accounts payable                                   351,189            76,098  
  Accrued liabilities                                 76,737           -41,146  
  Deferred revenue                                     5,195            43,079  
  Earn-out consideration                             -12,058                 —  
  Deferred acquisition                                -9,089                 —  
  payable                                                                       
  Operating lease                                     -9,405              -664  
  liabilities                                                                   
  Other long-term                                      1,519                 —  
  liabilities                                                                   
  Net cash provided by                                                          
  operating                                          118,810           238,694  
  activities                                                                    
  Investing activities                                                          
  Purchases of                                                                  
  available-for-sale                                       —          -713,556  
  investments                                                                   
  Maturities of                                                                 
  available-for-sale                                 142,522            72,757  
  investments                                                                   
  Proceeds from sales of                                                        
  available-for-sale                                 448,814                 —  
  investments                                                                   
  Purchases of property,                                                        
  equipment, and                                     -89,050          -166,657  
  intangible assets                                                             
  Investment in website                                                         
  development and                                    -18,947           -12,053  
  internal-use software                                                         
  Deferred consideration                                                        
  paid for                                          -130,346                 —  
  acquisition                                                                   
  Acquisition of                                                                
  businesses, net of                                -318,108          -121,773  
  cash                                                                          
  acquired                                                                      
  Purchases of equity                                -11,217                 —  
  securities                                                                    
  Payments for                                       -10,000                 —  
  investment earn-outs                                                          
  Net cash provided by                                                          
  (used in) investing                                 13,668          -941,282  
  activities                                                                    
  Financing activities                                                          
  Proceeds from issuance                                                        
  of convertible                                     390,425           970,000  
  senior notes, net of                                                          
  debt discount                                                                 
  Purchases of capped                                                           
  calls related to                                   -36,748           -47,800  
  convertible senior                                                            
  notes                                                                         
  Proceeds from exercise                                                        
  of vested stock                                     13,282             9,796  
  options                                                                       
  Payments for taxes                                                            
  related to net share                               -81,232           -94,955  
  settlement of equity                                                          
  awards                                                                        
  Proceeds from employee                                                        
  stock purchase                                       3,846             2,970  
  plan                                                                          
  Payments for                                                                  
  acquisition-related                                -43,682                 —  
  earn-out consideration                                                        
  Payments for debt                                     -939            -3,390  
  issuance costs                                                                
  Repurchases of common                                    —            -9,479  
  stock                                                                         
  Net cash provided by                                                          
  financing                                          244,952           827,142  
  activities                                                                    
  Foreign currency                                                              
  effect on cash and                                    -442              -216  
  cash                                                                          
  equivalents                                                                   
  Increase in cash, cash                                                        
  equivalents, and                                   376,988           124,338  
  restricted cash                                                               
  Cash, cash                                                                    
  equivalents, and                                                              
  restricted                                         228,616           221,440  
  cash at beginning of                                                          
  period                                                                        
  Cash, cash                                                                    
  equivalents, and          $                        605,604    $      345,778  
  restricted                                                                    
  cash at end of period                                                         
  Supplemental                                                                  
  disclosures of cash                                                           
  flow                                                                          
  information                                                                   
  Cash (received) paid                                                          
  for taxes, net of         $                         -2,168    $       23,430  
  refunds                                                                       
  Cash paid for interest                               2,121                 —  
  Non-cash investing and                                                        
  financing                                                                     
  activities                                                                    
  Purchases of property,                                                        
  equipment, and                                                                
  intangible assets         $                         11,718    $       36,841  
  included in accounts                                                          
  payable and accrued                                                           
  liabilities                                                                   
  Right-of-use asset                                                            
  obtained in exchange                                40,166           132,837  
  for lease liability                                                           
  Common stock issued,                                                          
  contingent and                                                                
  deferred                                                                      
  consideration,                                                                
  additional                                         886,287           193,890  
  consideration payable,                                                        
  and liabilities                                                               
  assumed in connection                                                         
  with acquisition                                                              
  of businesses                                                                 
  Proceeds from sales of                                                        
  equity securities                                   33,583                 —  
  included in                                                                   
  receivables, net                                                              
  Issuance of common                                                            
  stock in connection                                      —            12,760  
  with asset acquisition                                                        
  Common stock to be                                                            
  issued for asset                                                              
  acquisition                                              —             6,380  
  indemnification                                                               
  holdback                                                                      
                                                                                
                                                                                
  Non-GAAP Financial Measures                                                   
                                                                                
In addition to our financial results determined in accordance with U.S. GAAP, we
present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA
margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP
financial measure), each as defined below. We also present Adjusted Gross
Profit, Adjusted Marketing, Adjusted Operations and support, Adjusted Technology
and development, Adjusted General and administrative (collectively, Adjusted
Operating Expenses), and Adjusted Net Income (Loss) (each of which are non-GAAP
financial measures). We use Adjusted EBITDA, Adjusted EBITDA margin, Free Cash
Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net
Income (Loss) to evaluate our ongoing operations and for internal planning and
forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin,
Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted
Net Income (Loss), when taken together with the corresponding U.S. GAAP
financial measures, provide meaningful supplemental information regarding our
performance by excluding certain items that may not be indicative of our
business, results of operations, or outlook. We consider Adjusted EBITDA,
Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted
Operating Expenses, and Adjusted Net Income (Loss) to be important measures
because they help illustrate underlying trends in our business and our
historical operating performance on a more consistent basis. We believe that the
use of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross
Profit, Adjusted Operating Expenses, and Adjusted Net Income (Loss) is helpful
to our investors as they are used by management in assessing the health of our
business, our operating performance, and our liquidity.

However, non-GAAP financial information is presented for supplemental
informational purposes only, has limitations as an analytical tool, and should
not be considered in isolation or as a substitute for financial information
presented in accordance with U.S. GAAP. In addition, other companies, including
companies in our industry, may calculate similarly-titled non-GAAP financial
measures or ratios differently or may use other financial measures or ratios to
evaluate their performance, all of which could reduce the usefulness of Adjusted
EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted
Operating Expenses, and Adjusted Net Income (Loss) as tools for comparison.
Reconciliations are provided below to the most directly comparable financial
measures stated in accordance with U.S. GAAP. Investors are encouraged to review
our U.S. GAAP financial measures and not to rely on any single financial measure
to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess
our operating performance. Because Adjusted EBITDA facilitates internal
comparisons of our historical operating performance on a more consistent basis,
we use this measure for business planning purposes. “Adjusted EBITDA” is defined
as net (loss) income before stock-based compensation; depreciation and
amortization; acquisition, transaction, and investment earn-out costs (which
includes (i) consideration paid for employee and nonemployee compensation with
vesting requirements incurred directly as a result of acquisitions, (ii)
transaction professional services, and (iii) earn-outs payable under non-
recurring investment agreements); other non-recurring items (which includes
other non-cash, non-recurring costs, such as costs incurred when exiting
insignificant lines of business, or other costs which are not related to
continuing business operations); foreign currency gains and losses, net;
restructuring and other related charges that are considered non-recurring;
payroll tax expense related to stock-based compensation; interest income and
expense, net; legal contingencies; impairment of long-lived assets; change in
fair value of liabilities; income taxes; and change in fair value of equity
securities. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by
revenue.

In the third quarter of 2026, we revised our definition of Adjusted EBITDA to
include foreign currency gains and losses, net as a result of our recent
international expansion. Foreign currency gains and losses, net were not
considered significant for prior periods and, accordingly, prior period
disclosures were not recast to conform to the current presentation.

In the first quarter of 2026, we announced a strategic shift for our United
States weight loss offering ("2026 US WL Announcement"). As a result, we evolved
our United States weight loss offering to match our global approach towards
providing access to branded GLP-1 medications, and offering access to compounded
GLP-1 medications

through our platform on a limited scale. In connection with the strategic shift,
we revised our definition of Adjusted EBITDA to include restructuring and other
related charges that are considered non-recurring, as we believe these costs are
distinguishable from ongoing operating costs and do not reflect current or
expected performance of our ongoing operations. These costs consist of inventory
write-downs, third-party costs, and non-recurring employee compensation charges,
all of which were incurred directly as a result of the 2026 US WL Announcement.
Additional restructuring and other related charges were incurred in the second
and third quarters of 2026, and to the extent that we incur further
restructuring and other related charges in connection with the 2026 US WL
Announcement in future periods, these costs will be presented consistently with
our current presentation. As we did not record any non-recurring restructuring
and other related charges in prior years, prior period disclosures were not
impacted.

In the second quarter of 2025, we revised our definition of Adjusted EBITDA to
include payroll tax expense related to stock-based compensation, which comprises
employer taxes incurred upon vesting of restricted stock units and upon exercise
of nonqualified stock options. As a result of recent trends in our stock price,
this amount was not considered significant for prior periods and, accordingly,
prior period disclosures were not recast to conform to the current presentation.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not
properly reflect capital commitments to be paid in the future, and (ii) although
depreciation and amortization are non-cash charges, the underlying assets may
need to be replaced and Adjusted EBITDA does not reflect these capital
expenditures. In evaluating Adjusted EBITDA, you should be aware that in the
future we will incur expenses similar to the adjustments in this presentation.
Our presentation of Adjusted EBITDA should not be construed as an inference that
our future results will be unaffected by these expenses or any unusual or non-
recurring items. We compensate for these limitations by providing specific
information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When
evaluating our performance, you should consider Adjusted EBITDA in addition to,
and not as a substitute for, other financial performance measures, including our
net (loss) income and other U.S. GAAP results.
                                                                                
  Net (Loss) Income                                                             
                                                                                
                                                                                
  to Adjusted EBITDA Reconciliation                                             
                                                                                
(In Thousands, Unaudited)
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Rev…    $     890,…       $     598,…       $     2,25…       $     1,72…     
  Net                                                                           
  (lo…          -33,…             15,7…             -211…             107,…     
  inc…                                                                          
  Sto…          64,4…             40,1…             143,…             100,…     
  com…                                                                          
  Dep…                                                                          
  and           38,2…             17,6…             89,6…             36,4…     
  amo…                                                                          
  Acq…                                                                          
  tra…                                                                          
  and           35,4…             5,838             77,6…             12,0…     
  inv…                                                                          
  ear…                                                                          
  cos…                                                                          
  Oth…                                                                          
  non…          5,599                 —             5,599                 —     
  ite…                                                                          
  For…                                                                          
  cur…                                                                          
  gai…          4,064                 —             4,064                 —     
  and                                                                           
  los…                                                                          
  net                                                                           
  Res…                                                                          
  and                                                                           
  oth…          3,825                 —             41,9…                 —     
  rel…                                                                          
  cha…                                                                          
  Pay…                                                                          
  tax                                                                           
  exp…                                                                          
  rel…          1,277             2,314             6,166             5,392     
  to                                                                            
  sto…                                                                          
  com…                                                                          
  Int…                                                                          
  inc…                                                                          
  and             702             -8,0…             -6,5…             -16,…     
  exp…                                                                          
  net                                                                           
  Leg…              —                 —             62,5…                 —     
  con…                                                                          
  Imp…                                                                          
  of                —               531             1,148               531     
  lon…                                                                          
  ass…                                                                          
  Cha…                                                                          
  in                                                                            
  fair          -3,8…             7,626             18,0…             7,626     
  val…                                                                          
  of                                                                            
  lia…                                                                          
  Ben…                                                                          
  from          -13,…             -3,5…             -28,…             -2,1…     
  inc…                                                                          
  tax…                                                                          
  Cha…                                                                          
  in                                                                            
  fair                                                                          
  val…          -21,…                 —             -16,…                 —     
  of                                                                            
  equ…                                                                          
  sec…                                                                          
  Adj…    $     82,3…       $     78,3…       $     186,…       $     251,…     
  EBI…                                                                          
  Net                                                                           
  (lo…                                                                          
  inc…             -4  %              3  %             -9  %              6  %  
  as a                                                                          
  % of                                                                          
  rev…                                                                          
  Adj…                                                                          
  EBI…              9  %             13  %              8  %             15  %  
  mar…                                                                          
                                                                                
Free Cash Flow is a key performance measure that our management uses to assess
our liquidity. Because Free Cash Flow facilitates internal comparisons of our
historical liquidity on a more consistent basis, we use this measure for
business planning purposes. “Free Cash Flow” is defined as net cash provided by
operating activities, less purchases of property, equipment, and intangible
assets and investment in website development and internal-use software in
investing activities.

Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not
represent our residual cash flow for discretionary expenditures and our non-
discretionary commitments, and (ii) Free Cash Flow includes capital
expenditures, the benefits of which may be realized in periods subsequent to
those in which the expenditures took place. In evaluating Free Cash Flow, you
should be aware that in the future we will have cash outflows similar to the
adjustments in this presentation. Our presentation of Free Cash Flow should not
be construed as an inference that our future results will be unaffected by these
cash outflows or any unusual or non-recurring items. When evaluating our
performance, you should consider Free Cash Flow in addition to, and not as a
substitute for, other financial performance measures, including our net cash
provided by operating activities and other U.S. GAAP results.
Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation
(In Thousands, Unaudited)
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  provid…    $      65,393    $     148,721    $      118,810    $     238,694  
  by                                                                            
  operat…                                                                       
  activi…                                                                       
  Purcha…                                                                       
  of                                                                            
  proper…                                                                       
  equipm…                                                                       
  and              -33,280          -65,265           -89,050          -166,6…  
  intang…                                                                       
  assets                                                                        
  in                                                                            
  invest…                                                                       
  activi…                                                                       
  Invest…                                                                       
  in                                                                            
  website                                                                       
  develo…                                                                       
  and               -6,139           -4,092           -18,947          -12,053  
  intern…                                                                       
  softwa…                                                                       
  in                                                                            
  invest…                                                                       
  activi…                                                                       
  Free                                                                          
  Cash       $      25,974    $      79,364    $       10,813    $      59,984  
  Flow                                                                          
                                                                                
Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income
(Loss) are key performance measures that our management uses to assess our
operating performance. Because Adjusted Gross Profit, Adjusted Operating
Expenses, and Adjusted Net Income (Loss) facilitate internal comparisons of our
historical operating performance on a more consistent basis, we use these
measures for business planning purposes. “Adjusted Gross Profit” is defined as
gross profit adjusted for restructuring and other related charges included
within cost of revenue. “Adjusted gross margin” is defined as Adjusted Gross
Profit divided by revenue. “Adjusted Marketing” is defined as marketing expense
adjusted for stock-based compensation. “Adjusted Operations and support” is
defined as operations and support expense adjusted for stock-based compensation
and restructuring and other related charges included within operating expenses.
“Adjusted Technology and development” is defined as technology and development
expense adjusted for acquisition, transactions, and investment earn-out costs
and stock-based compensation. “Adjusted General and administrative” is defined
as general and administrative expense adjusted for stock-based compensation,
acquisition, transaction, and investment earn-out costs, and legal
contingencies. “Adjusted Net Income (Loss)” represents Net (Loss) Income
adjusted for acquisition, transaction, and investment earn-out costs,
restructuring and other related charges, and legal contingencies, net of related
tax effects.

Some of the limitations of Adjusted Gross Profit, Adjusted Operating Expenses,
and Adjusted Net Income (Loss) include that they omit certain costs and charges,
and therefore do not reflect all expenses that impact the corresponding U.S.
GAAP results. In evaluating Adjusted Gross Profit, Adjusted Operating Expenses,
and Adjusted Net Income (Loss), you should be aware that in the future we may
incur expenses similar to the adjustments in this presentation. Our presentation
of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income
(Loss) should not be construed as an inference that our future results will be
unaffected by these expenses or any unusual or non-recurring items. We
compensate for these limitations by providing specific information regarding the
U.S. GAAP items excluded from Adjusted Gross Profit, Adjusted Operating
Expenses, and Adjusted Net Income (Loss). When evaluating our performance, you
should consider Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted
Net Income (Loss) in addition to, and not as a substitute for, other financial
performance measures, including our net (loss) income and other U.S. GAAP
results.
Gross Profit to Adjusted Gross Profit Reconciliation

(In Thousands, Unaudited)
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Rev…    $     890,…       $     598,…       $     2,25…       $     1,72…     
  Gro…          509,…             442,…             1,38…             1,28…     
  Pro…                                                                          
  Res…                                                                          
  and                                                                           
  oth…                                                                          
  rel…                                                                          
  cha…              —                 —             28,4…                 —     
  inc…                                                                          
  wit…                                                                          
  cost                                                                          
  of                                                                            
  rev…                                                                          
  Adj…                                                                          
  Gro…    $     509,…       $     442,…       $     1,41…       $     1,28…     
  Pro…                                                                          
  Gro…                                                                          
  mar…             57  %             74  %             62  %             75  %  
  %                                                                             
  Adj…                                                                          
  gro…             57  %             74  %             63  %             75  %  
  mar…                                                                          
  %                                                                             
                                                                                
Operating Expenses to Adjusted Operating Expenses Reconciliation

(In Thousands, Unaudited)
                                                                                
                     Three                                Nine                  
                    Months                              Months                  
                     Ended                               Ended                  
                    Septe…                             Septem…                  
              2026     30,    2025               2026      30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Mark…          $  247,2…       $  232,150         $  731,519       $  681,2…  
  Stoc…             -4,135           -3,116             -9,954          -9,325  
  comp…                                                                         
  Adju…          $  243,1…       $  229,034         $  721,565       $  671,9…  
  Mark…                                                                         
             Three                               Nine                           
            Months                             Months                           
             Ended                              Ended                           
           Septem…                             Septe…                           
               30,                                30,                           
              2026            2025               2026             2025          
  Oper…                                                                         
  and            $  107,1…       $   76,848         $  299,180       $  206,3…  
  supp…                                                                         
  Stoc…             -10,8…           -5,452            -23,993          -13,0…  
  comp…                                                                         
  Rest…                                                                         
  and                                                                           
  other                                                                         
  rela…                                                                         
  char…             -3,825                —            -13,477               —  
  incl…                                                                         
  with…                                                                         
  oper…                                                                         
  expe…                                                                         
  Adju…                                                                         
  Oper…          $  92,507       $   71,396         $  261,710       $  193,3…  
  and                                                                           
  supp…                                                                         
             Three                               Nine                           
            Months                             Months                           
             Ended                              Ended                           
           Septem…                             Septe…                           
               30,                                30,                           
              2026            2025               2026             2025          
  Tech…                                                                         
  and            $  69,387       $   40,577         $  171,224       $  108,3…  
  deve…                                                                         
  Acqu…                                                                         
  tran…                                                                         
  and               -12,5…           -1,977            -18,946          -4,962  
  inve…                                                                         
  earn…                                                                         
  costs                                                                         
  Stoc…             -12,5…           -4,842            -25,190          -14,1…  
  comp…                                                                         
  Adju…                                                                         
  Tech…          $  44,240       $   33,758         $  127,088       $  89,243  
  and                                                                           
  deve…                                                                         
             Three                               Nine                           
            Months                             Months                           
             Ended                              Ended                           
           Septem…                             Septe…                           
               30,                                30,                           
              2026            2025               2026             2025          
  Gene…                                                                         
  and            $  151,4…       $   80,676         $  426,527       $  196,5…  
  admi…                                                                         
  Stoc…             -36,9…          -26,762            -84,318          -64,2…  
  comp…                                                                         
  Acqu…                                                                         
  tran…                                                                         
  and               -22,8…           -3,861            -58,672          -7,131  
  inve…                                                                         
  earn…                                                                         
  costs                                                                         
  Legal                  —                —            -62,500               —  
  cont…                                                                         
  Adju…                                                                         
  Gene…          $  91,734       $   50,053         $  221,037       $  125,1…  
  and                                                                           
  admi…                                                                         
                                                                                
Net (Loss) Income to Adjusted Net Income (Loss) Reconciliation

(In Thousands, Unaudited)
                                                                                
                      Three                              Nine                   
                     Months                            Months                   
                      Ended                             Ended                   
                   Septemb…                          Septemb…                   
             2026       30,    2025            2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  (loss)     $      -33,040    $     15,774    $     -211,445    $     107,764  
  income                                                                        
  Acquis…                                                                       
  transa…                                                                       
  and                35,417           5,838            77,618           12,093  
  invest…                                                                       
  earn-o…                                                                       
  costs                                                                         
  Restru…                                                                       
  and                                                                           
  other               3,825               —            41,939                —  
  related                                                                       
  charges                                                                       
  Legal                   —               —            62,500                —  
  contin…                                                                       
  Tax                                                                           
  effects               269          -1,118           -28,494           -1,118  
  of                                                                            
  adjust…                                                                       
  Adjust…                                                                       
  Net        $        6,471    $     20,494    $      -57,882    $     118,739  
  Income                                                                        
  (Loss)                                                                        
                                                                                
Contacts:
                                                                                
  Investor Relations                                                            
                                                                                
Bill Newby

[email protected]
                                                                                
  Media Relations                                                               
                                                                                
Abby Reisinger-Moley

[email protected]

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HIMS/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.